Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval & Atorvastatin patent filing

Supriya Lifescience Ltd., a global pharmaceutical industry leader, achieved two significant milestones, strengthening its position in international markets. The company has acquired approval from Brazil's health authority, ANVISA (Agência Nacional de Vigilância Sanitária), for Esketamine Hydrochloride, which is a major step in growing its product range in Brazil and the rest of LATAM. Supriya Lifescience is the first firm in Brazil to have received regulatory permission for this highly specialised pharmaceutical.

Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market. This approval will enable the company to provide state-of-the-art, high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing.

Moreover, the business submitted a ground-breaking patent application for an enhanced, low-cost method of atorvastatin synthesis. This ground-breaking technique makes drugs more affordable for patients by increasing their efficacy while reducing production costs. Global healthcare relies heavily on atorvastatin, a key treatment for controlling cholesterol and preventing cardiovascular disease, and this achievement shows Supriya's dedication to drug cost and raising accessibility.

Dr. Satish Wagh, Executive Chairman and Whole Time Director, Supriya Lifescience Ltd. stated, "Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin. Our global presence is strengthened by the CADIFA approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil."

With CADIFA approval in place, Supriya Lifescience is now ready to tap into the fastgrowing LATAM market. The company's continued focus on innovation, regulatory compliance, and its mission to make high-quality healthcare accessible globally positions it as a key player in the international pharmaceutical landscape.

Shares of Supriya Lifescience Limited was last trading in BSE at Rs. 778.05 as compared to the previous close of Rs. 804.30. The total number of shares traded during the day was 13046 in over 699 trades.

The stock hit an intraday high of Rs. 804.00 and intraday low of 773.05. The net turnover during the day was Rs. 10307159.00.

Source : Equity Bulls

Keywords

SupriyaLifescience INE07RO01027 Pharmaceuticals Milestones Internationalmarkets ANVISA Approval EsketamineHydrochloride